RxDoctor Payments Data

Dmitry Konsky, DO

Internal Medicine · Oceanside, NYNPI 1720085061

Payments from drug & device makers

$1,011in general payments, 2019–2025

Across 37 payments — averaging $27.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$567
  • AstraZeneca$118
  • E.r. Squibb & Sons, L.L.C.$101
  • Gilead$63
  • Pfizer$56
  • Shionogi Inc$47
  • plus $59 from 2 others

What the payments were for

  • Food & beverage$1,011100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson21$567
AstraZeneca(2 entities)3$118
E.r. Squibb & Sons, L.L.C.5$101
Gilead2$63
Pfizer2$56
Shionogi Inc1$47
Merck2$34
Novartis1$25

How this compares

$1,011 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$201,464
Medicare patients
507
Services billed
1,711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban103$35,178
XareltoRivaroxaban31$10,062
NuedextaDextromethorphan Hbr/Quinidine11$8,574
EntrestoSacubitril/Valsartan18$6,191
JanuviaSitagliptin Phosphate11$4,806
GemtesaVibegron19$4,446
Memantine Hcl112$3,381
Sucralfate23$3,320
Atorvastatin Calcium226$2,032
Mirtazapine117$2,028
Valproic AcidValproic Acid (As Sodium Salt)18$1,979
Donepezil Hcl119$1,844
Divalproex Sodium34$1,652
Levothyroxine Sodium170$1,558
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc13$1,480

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$56$35,178103 claims
Johnson & JohnsonXarelto$567$10,06231 claims
NovartisEntresto$25$6,19118 claims
MerckJanuvia$34$4,80611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Oceanside

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →